The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis (Q35212555)

7 August 2017

1 reference

title

The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis (English)

1 reference

7 August 2017

1 reference

1 reference

Jorge Plutzky

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

American Journal of Cardiology

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

34J-41J

1 reference

Inflammation and atherosclerosis

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Inflammatory pathways in atherosclerosis and acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Changing concepts of atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Current concepts of the pathogenesis of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Atherosclerotic plaque rupture: emerging insights and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Basic mechanism of leukocyte migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Chemokines — Chemotactic Cytokines That Mediate Inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Chemokine signaling in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Atherosclerosis. the road ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

CD40 ligation induces tissue factor expression in human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Mouse models of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Direct proinflammatory effect of C-reactive protein on human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The nuclear receptor superfamily: the second decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The PPARs: from orphan receptors to drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Thiazolidinediones: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The peroxisome proliferator-activated receptors: ligands and activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARdelta is a very low-density lipoprotein sensor in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptors in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) activation in naive mouse T cells induces cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900614-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(03)00614-3

1 reference

7 August 2017

1 reference